Cargando…

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study

BACKGROUND: Rheumatoid arthritis (RA) is a heterogeneous disease with established poor prognostic factors such as seropositivity, joint damage, and high disease activity at an early, treatment-naïve stage of disease. However, few studies have examined if specific joint locations are correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durez, Patrick, Westhovens, Rene, Baeke, Femke, Elbez, Yedid, Robert, Sofie, Ahmad, Harris A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009012/ https://www.ncbi.nlm.nih.gov/pubmed/35418172 http://dx.doi.org/10.1186/s41927-022-00252-4

Ejemplares similares

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
por: Westhovens, R., et al.
Publicado: (2020)

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
por: Aletaha, Daniel, et al.
Publicado: (2021)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
por: Vander Cruyssen, Bert, et al.
Publicado: (2006)

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study
por: De Mits, Sophie, et al.
Publicado: (2016)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Anatomical location of erosions at the metatarsophalangeal joints in patients with rheumatoid arthritis
por: Siddle, Heidi J., et al.
Publicado: (2014)

Editorial: Risk factors for Rheumatoid Arthritis and pre-Rheumatoid Arthritis
por: Sapart, Emillie, et al.
Publicado: (2022)

Does ultrasound agree with parent's perception of joint disease in juvenile idiopathic arthritis?
por: Biancardi, Carlo, et al.
Publicado: (2014)

Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques
por: Put, Stéphanie, et al.
Publicado: (2014)

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
por: Ahmad, Harris A., et al.
Publicado: (2020)

An analysis of intra array repeats: the good, the bad and the non informative
por: Elbez, Yedid, et al.
Publicado: (2006)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Tender and swollen joint counts are poorly associated with disability in chikungunya arthritis compared to rheumatoid arthritis
por: Watson, Hugh, et al.
Publicado: (2021)

Joint Location–Specific JAK‐STAT Signaling in Rheumatoid Arthritis Fibroblast‐like Synoviocytes
por: Hammaker, Deepa, et al.
Publicado: (2019)

External location of touch is constructed post-hoc based on limb choice
por: Maij, Femke, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
por: Tesser, John, et al.
Publicado: (2023)

One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment
por: Van der Elst, Kristien, et al.
Publicado: (2020)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

The Treatment of Joints in Rheumatoid Arthritis
por: Lindsay, James
Publicado: (1907)

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
por: Constantin, Arnaud, et al.
Publicado: (2022)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
por: Taylor, Peter C., et al.
Publicado: (2022)

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
por: Emery, Paul, et al.
Publicado: (2023)

Why Did the Earwitnesses to the John F. Kennedy Assassination Not Agree About the Location of the Gunman?
por: McFadden, Dennis
Publicado: (2021)

Rheumatoid arthritis affecting temporomandibular joint
por: Sodhi, Amandeep, et al.
Publicado: (2015)

Prevalence of Elbow Joint Arthritis and Enthesitis in Rheumatoid Arthritis
por: Schäfer, Valentin Sebastian, et al.
Publicado: (2020)

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
por: Cruyssen, Bert Vander, et al.
Publicado: (2006)

Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis
por: Michaël, Doumen, et al.
Publicado: (2021)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nfq1d4fre0ef6phkkghp3es8h4